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HOSPITAL BURDEN RELATED TO UPPER AERODIGESTIVE TRACT 
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ST[E]VE Consultants, Lyon, France
OBJECTIVES: Upper Aerodigestive Tract (UAT) cancers concern more than 20,000 
new cases and about 10,000 deaths per year in France and represent the highest inci-
dence in Europe. In the scope of optimising local health care offer, the purpose of this 
study was to assess and compare the annual hospital burden of UAT cancers in every 
French region. METHODS: We used the 2007 PMSI French hospital database gather-
ing information on public and private hospitals admissions. Through an algorithm 
based on ICD10 diagnosis, we extracted hospital stays, chemotherapy and radiother-
apy sessions for UAT cancers (malignancies affecting the oral cavity, salivary glands, 
facial airways, oropharynx, hypopharynx and larynx). Radiotherapy sessions per-
formed in the private sector are not registered in the PMSI, so they were assessed from 
the SAE database. Hospital charges were based on a representative national cost study 
(ENC) and demography data were extracted from National statistics (INSEE). 
RESULTS: In 2007, 274,082 records for UAT cancers were extracted from the PMSI 
corresponding to 35,085 patients, of which 81% were men. This gender disparity is 
homogeneous over UAT cancer types, except for salivary glands cancer affecting up 
to 60% of men. The prevalence of hospitalised patients suffering from UAT cancers 
was higher in Northern regions. By including radiotherapy sessions performed in 
private sector, the annual hospital charge was estimated at a330,977,982, of which 
75.0% and 15.3% were dedicated to hospital stays and chemotherapy sessions respec-
tively. Radiotherapy sessions represent 9.7% of total charge, ranging from 5.6% to 
17.8% according to regions. CONCLUSIONS: In France, UAT cancers represent a 
heavy charge for hospitals. Furthermore, regional disparities are signiﬁcant. In a  
context of the regionalization of health plans, these results could be useful for decision 
makers in order to develop adapted prevention programs and relevant resources allo-
cation at local level.
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OBJECTIVES: To estimate the resource utilization and microcosting related to endo-
crine therapy (ET) versus chemotherapy (CT) in the treatment of hormonal receptor 
positive (HR), advanced breast cancer (ABC) patients, after at least one previous ET, 
under the BPHS perspective. METHODS: This retrospective longitudinal study ana-
lyzed ABC patients receiving fulvestrant or CT between 2006 and 2008 in a public 
oncology outpatient service. The study sample was a convenience sample and included 
all eligible patients identiﬁed. Only patients without visceral crisis and with at least 
one previous hormonal therapy were considered eligible. Medical charts were reviewed 
by two investigators and information about diagnosis, course of treatment, and 
resource utilization was obtained. Unit costs were obtained from public Brazilian 
databases. RESULTS: Patients were all female and the mean age was 64.6 o 12.6 
years. Patients were well matched between groups considering baseline characteristics. 
Twenty-ﬁve patients were enrolled in the study, 13 patients received CT and 12 
patients received fulvestrant. The most common CT regimen was paclitaxel (n  5, 
38%). The mean number of cycles was 7,6 and 5,8 for fulvestrant and CT, respec-
tively. The mean treatment cost per patient was BRL16,679 (US$11,914; 2005 pur-
chasing power parity index 1US$  1.4BRL) for fulvestrant and BRL32,946 
(US$23,533) for CT. The mean cost per cycle was BRL2199 (US$1571) and BRL5710 
(US$4079) for fulvestrant and CT, respectively, resulting in BRL3511 (US$2508) 
incremental cost per cycle. Medications were the largest contributor to overall cost, 
corresponding to 97% and 92% of total costs per cycle in the fulvestrant and chemo-
therapy groups, respectively. CONCLUSIONS: Our study results indicate that subse-
quent ET with fulvestrant can be economically appropriate among HR ABC patients. 
Further researches could validate these ﬁndings in other contexts, but we consider that 
our estimations reﬂect the real world clinical practice in Brazil.
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OBJECTIVES: This study reviewed published direct and indirect costs estimates 
associated with the management of chemotherapy induced peripheral neuropathy 
(CIPN), a frequent side effect of neurotoxic chemotherapies affecting activities of daily 
living. METHODS: A systematic search of six article databases including EMBASE,     
Medline, EMBR, HAPI, IPA, CINAHL and four conference proceedings between 2003 
and 2009 was undertaken using clinical, chemotherapy, and economic related terms.         
RESULTS: Of the 8262 articles and 355 conference abstracts that were identiﬁed, a 
total of 7 articles and 1 abstract discussed economic impact. Only one study reported 
direct and indirect costs from a societal perspective and the others measured only 
direct costs from the payer’s perspective. Neuropathy related resource use was not 
consistently measured, and no studies reported clinical testing or rehabilitation costs. 
Although CIPN symptoms linger for months after treatment ends, no study measured 
resource use beyond the duration of chemotherapy treatment. Total societal cost of 
CIPN was estimated to be $4908/episode. Direct treatment cost ranged from $150–
$688/episode, with medication and physician consultation costs accounting for the 
majority of these costs. Physician consultation costs ranged from $150–$300. The cost 
of a grade 4 neuropathy hospitalization was approximately $8095 for a four day stay. 
Indirect costs of CIPN were estimated to be $4220/episode, accounting for 86% of 
the total neuropathy-related costs. These costs included lost salary, paid caregiver, 
travel expenses. The caregiver’s work loss accounted for 82% of the total indirect 
costs. CONCLUSIONS: Total societal costs of CIPN are signiﬁcant. Indirect costs, 
including lost work productivity, account for the majority of total CIPN costs. 
Resource use and costs of treatment were likely underreported given that studies did 
not account for post-chemotherapy resource use. More accurate estimates of costs and 
resource use are necessary to understand the true economic impact of CIPN.
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OBJECTIVES: Tyrosine kinase inhibitors (TKIs), such as imatinib and dasatinib, have 
revolutionized treatment for chronic myelogenous leukemia (CML). Randomized trials 
suggest that TKIs differentiate according to both efﬁcacy and rates of adverse events, 
which may translate in to differences in cost-effectiveness ratios. While some data exist 
on the resource use and costs of CML treatment in the US, no similar UK data exist. 
However, differences in the management and costs of treatment of CML exist between 
the US and the UK. The objective of this study was therefore to calculate UK-speciﬁc 
resource use and costs estimates associated with the treatment of CML. METHODS: 
Using a questionnaire based on current treatment guidelines and clinical expert con-
sultation, we elicited the opinion of six oncologists on the frequency of resource use 
(outpatient visits, laboratory tests, interventions and hospitalization). Estimates were 
stratiﬁed by disease phase (chronic, accelerated, or blast), treatment response status 
(responding or not) and treatment duration. Mean costs (minimum, maximum) in 
2008 GBP were obtained from publicly available sources. RESULTS: In the ﬁrst three 
months of each phase, a patient responding to treatment was estimated to cost: £730 
(£153, £1229) in chronic phase, £867 (£176, £1473) in accelerated phase, and £2659 
(£590, £6014) in blast phase. A patient not responding to treatment was estimated to 
cost £901 (£429, £1327) in chronic phase, £1012 (£437, £1416) in accelerated phase, 
and £4486 (£964, £7507) in blast phase. Costs were higher for patients not responding 
to treatment, increased as patients progressed through disease phases, and decreased 
with increasing time in the phase. CONCLUSIONS: Higher costs were associated with 
patients not responding to treatment in each CML phase. The estimates collected in 
the current study can supplement existing data on the economic burden of CML, and 
will serve as reproducibly-measured inputs for future models.
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OBJECTIVES: We examined drivers of hospital costs and DRG reimbursement 
adequacy for inpatient cases of progressive malignant thoracic neoplasm in a 
large German university hospital. METHODS: This was a prospective observational 
study, which enrolled the ﬁrst 84 patients with progressive malignant thoracic 
neoplasm admitted to the oncology department of Munich Ludwig-Maximilian Uni-
versity Hospital in 2008. The economic evaluation was performed from the hospital 
perspective and costs are reported at current prices. Demographic data, medical 
history and disease management information were collected in case report forms. 
Detailed hospital costs and health insurance reimbursements were obtained from 
hospital’s analytical accounting system. We explored factors associated with inpatient 
cost in a Generalized Linear Model with log link and Gamma distribution. RESULTS: 
The analysis sample included 80 patients (67.5% males) with a mean age of 63.4 
years (SD 10.6), of which 52 (65.0%) were publicly insured only. Main reasons for 
hospitalization were cancer therapy and/or management of therapy complications 
(47.5%). Thirty-nine patients (48.8%) had a histology of non-small cell carcinoma 
and 33 (41.3%) of small cell carcinoma. Sixty-seven patients (83.8%) had metastatic 
disease and the median Karnofsky performance status index was 80% (IQR 20%). 
The mean length of stay was 9.7 days (SD 10.1) and the mean inpatient cost a4892, 
two times higher than the median (a2499). Drugs, medical personnel and hospital 
infrastructures accounted for 32.9%, 25.3% and 20.7% of hospitalization costs, 
respectively. The multivariate analysis revealed signiﬁcant positive associations (p  
0.01) between lower performance status, non-small cell histology, number of reasons 
for hospitalization, as a proxy of case complexity, and inpatient cost. On average, 
cost exceeded by a1166 health insurance reimbursement. CONCLUSIONS: We found 
strong impact of case severity, complexity and tumor histology on inpatient cost. DRG 
reimbursement is overall insufﬁcient to cover hospital costs due to the cost-intensive 
cases.
